Procollagen-III-peptide

Procollagen-III-peptide was detected by H. Rohde et al. in 1978. The results of P-III-P determination in liver diseases were presented by the same research group in 1979. P-III-P determination is less important for diagnosis, but it facilitates monitoring the course of a liver disease with respect to the current degree of fibrosis. This makes it possible to obtain information on the activity (= connective tissue formed per unit of time) and reversibility of liver fibrosis. Thus there is a good correlation between P-III-P concentrations and the histomor-phometrically estimated fibrosis activities. 

Bayerdorffer, E., Lamerz, R., Fliege, R., Kopcke, W., Mannes, G.A. Predictive value of serum procollagen-III-peptide for the survival of patients with cirrhosis. J. Hepatol. 1991 13 298-304... 

Bell, H., Raknerud, N., Orjaseter, H., Haug, E. Serum procollagen III peptide in alcoholic and other chronic liver diseases. Scand. J. Gastroenterol. 1989 24 1217-1222... 

The major clinical manifestation of AAT deficiency is emphysema, which tends to occur at an earlier age and can occur in the absence of smoking. It is estimated that 1% of emphysema is related to AAT deficiency. In neonates, AAT deficiency is often associated with hepatitis in one study, almost one third of infants with prolonged jaundice were found to be AAT deficient. About 20% of AAT deficient infants develop hepatitis, with up to 25% 1-year mortality. In those who survive the first year, however, evidence of liver injury diminishes and usually resolves by age 12. At age 18, none of 183 individuals with AAT deficiency had clinical evidence of liver disease, none had elevated procollagen III peptide, and less than 20% had elevated liver-associated enzymes. These findings suggest that AAT may have minimal effects on pathogenesis of liver disease in adults." ... 

Cantin, A.M., Boileau, R. and Begin, K (1988). Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lung of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 137, 572-578. 

Cho, J-J., and Y-S. Lee. 1998. Enzyme linked immunosorbent assay for serum procollagen type III peptide in rats with hepatic fibrosis. Journal of Veterinary Medical Science 60 1213-1220. 

Blood Alkaline phosphatase (bone-specific) Osteocalcin Procollagen type I carboxy-terminal propeptide (PICP) Procollagen type I amino-terminal propeptide (PINP) Procollagen type III amino-terminal propeptide (PIIINP) Blood Acid phosphatase (acid-resistant) Type I collagen carboxy-terminal telopeptide (ICTP) Urine Calcium Hydroxyproline Cross-linked peptides (pyridinium and deoxypyridinoline)... 

Lotterer, E., Gressner, AJM., Kropf, J., Grobe, E., Knebel, von, D., Bircher, J. Higher levels of serum aminoterminal type III procollagen peptide, and laminin in alcoholic than in nonalcoholic cirrhosis of equal severity. J. Hepatol. 1992 14 71—77... 

Muller, A., Krombholz, B., Pott, G., Machnik, G., Vollandt, R., Reinhardt, M., Jorke, D. Collagen peptidase and type III procollagen peptide serum levels in chronic liver diseases. Clin. Chim. Acta 1991 197 59-66... 

Trinchet, J.-C., Hartmann, D.J., Pateron, D., Laarif, M., Callard, P., Ville, G., Beaugrand, M. Serum type 1 collagen and N-terminal peptide of type III procollagen in chronic hepatitis. J. Hepatol. 1991 12 139-144... 

Bjermer, L., Lundgren, R. and Haellgren, R. (1989). Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 44, 126-131. 

Low, KB., Cutroneo, K.K, Davis, G.S. et al. (1983). Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab, Invest. 48, 755-759. 

Low, KB., Giancola, M.S., King, T.E.Jr. etal. (1992). Serum and bronchoalveolar lavage N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 146, 701-706. 

Pugin et al. (75) compared IL-8, matrix metalloproteinases (MMP-2 and MMP-9), and procollagen peptide III in the pulmonary edema fluid of patients with ARDS or hydrostatic edema. IL-8, MMP-9, and PCPIII were all elevated in the ARDS edema fluid as compared with the hydrostatic edema fluids. The outcomes of the patients were not reported. Interestingly, the clinical severity of illness scores were similar in the patients with ARDS and cardiogenic edema, so the edema fluid measurements were better than clinical criteria at identifying the patients with severe lung injury. 

Clark, J. G., Milberg, J. A., Steinberg, K. P., and Hudson, L. D. (1995) Type III procollagen peptide in the adult respiratory distress syndrome association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann. Intern. Med. 122,17-23. 

---